A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Alpelisib (Primary) ; Exemestane; Letrozole
- Indications Breast cancer
- Focus Adverse reactions
- 16 Feb 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.
- 16 Feb 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2018.
- 16 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History